BIOMAT Database Logo BIOMAT Database Logo

Effects of human pancreatic tumour growth hormone releasing factor on growth hormone and somatomedin C levels in patients with idiopathic growth hormone deficiency. 1983

J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner

Human pancreatic tumour growth hormone releasing factor (hpGRF-40) 10 micrograms/kg was administered intravenously to 6 normal young men and 12 adult patients who had presented in childhood with growth hormone (GH) deficiency (7 patients had isolated GH deficiency, 4 had multiple anterior pituitary hormone deficiencies, and 1 had Hand-Schüller-Christian [HSC] disease). hpGRF-40 administration increased serum GH concentrations in all normal subjects and in 3 of 7 patients with isolated GH deficiency and in the 1 with HSC disease; however, the mean serum GH concentration in the patients who responded was less than that of the normal subjects. Somatomedin C concentrations were increased 24 h after a single dose of hpGRF-40 in 8 of 10 patients with GH deficiency. All subjects experienced flushing in response to hpGRF-40. A patient with isolated GH deficiency received 0.33 micrograms/kg hpGRF-40 every 3 h for 5 days. Despite the modest increase in GH in response to a subsequent dose of 10 micrograms/kg hpGRF-40, serum somatomedin C levels increased within 12 h from 0.06 to 0.1 U/ml and peaked at 0.36 U/ml at 72 h; in addition the patient with HSC disease, treated with hpGRF-40 daily for 5 days, demonstrated an increase in somatomedin C from 0.4 to 0.58 U/ml. The increase after hpGRF-40 in serum GH levels in this patient and the similar or greater responses in 3 of 7 patients suggest that at least some of these patients may have hypothalamic GH-releasing-hormone deficiency. hpGRF-40 may be useful in distinguishing pituitary disease from hypothalamic disease. After hpGRF-40 administration serum somatomedin C levels may increase without a change in serum immunoreactive GH concentrations. Further studies are needed to determine whether hpGRF-40 is useful in promoting linear growth in children with GH deficiency.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D004393 Dwarfism, Pituitary A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development. Growth Hormone Deficiency Dwarfism,Hypophysial Dwarf,Hyposomatotrophic Dwarfism,Pituitary Dwarf,Dwarfism, Growth Hormone Deficiency,Isolated GH Deficiency,Isolated Growth Hormone Deficiency,Isolated HGH Deficiency,Isolated Human Growth Hormone Deficiency,Isolated Somatotropin Deficiency,Isolated Somatotropin Deficiency Disorder,Nanism, Pituitary,Pituitary Dwarfism,Pituitary Nanism
D005260 Female Females
D006646 Histiocytosis, Langerhans-Cell A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder. Histiocytosis X,Langerhans-Cell Granulomatosis,Langerhans-Cell Histiocytosis,Hand-Schueller-Christian Disease,Hand-Schueller-Christian Syndrome,Hand-Schüller-Christian Disease,Hand-Schüller-Christian Syndrome,Hashimoto-Pritzger Disease,Histiocytosis, Generalized,Histiocytosis-X,Langerhans Cell Granulomatosis,Langerhans Cell Granulomatosis, Pulmonary,Langerhans Cell Histiocytosis,Letterer-Siwe Disease,Non-Lipid Reticuloendotheliosis,Pulmonary Histiocytosis X,Pulmonary Langerhans Cell Granulomatosis,Schueller-Christian Disease,Systemic Aleukemic Reticuloendotheliosis,Type 2 Histiocytosis,Aleukemic Reticuloendothelioses, Systemic,Aleukemic Reticuloendotheliosis, Systemic,Cell Granulomatoses, Langerhans,Cell Granulomatosis, Langerhans,Cell Histiocytoses, Langerhans,Cell Histiocytosis, Langerhans,Disease, Hand-Schueller-Christian,Disease, Hand-Schüller-Christian,Disease, Hashimoto-Pritzger,Disease, Letterer-Siwe,Disease, Schueller-Christian,Diseases, Hashimoto-Pritzger,Generalized Histiocytoses,Generalized Histiocytosis,Granulomatoses, Langerhans Cell,Granulomatosis, Langerhans Cell,Granulomatosis, Langerhans-Cell,Hand Schueller Christian Disease,Hand Schueller Christian Syndrome,Hand Schüller Christian Disease,Hand Schüller Christian Syndrome,Hashimoto Pritzger Disease,Hashimoto-Pritzger Diseases,Histiocytoses, Generalized,Histiocytoses, Langerhans Cell,Histiocytoses, Type 2,Histiocytosis X, Pulmonary,Histiocytosis, Langerhans Cell,Histiocytosis, Type 2,Langerhans Cell Granulomatoses,Langerhans Cell Histiocytoses,Letterer Siwe Disease,Non Lipid Reticuloendotheliosis,Non-Lipid Reticuloendothelioses,Reticuloendothelioses, Non-Lipid,Reticuloendothelioses, Systemic Aleukemic,Reticuloendotheliosis, Non-Lipid,Reticuloendotheliosis, Systemic Aleukemic,Schueller Christian Disease,Syndrome, Hand-Schueller-Christian,Syndrome, Hand-Schüller-Christian,Systemic Aleukemic Reticuloendothelioses,Type 2 Histiocytoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013002 Somatomedins Insulin-like polypeptides made by the liver and some fibroblasts and released into the blood when stimulated by SOMATOTROPIN. They cause sulfate incorporation into collagen, RNA, and DNA synthesis, which are prerequisites to cell division and growth of the organism. Sulfation Factor,Somatomedin,Factor, Sulfation

Related Publications

J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Plasma growth hormone (GH) and somatomedin C response to continuous growth hormone-releasing factor (GRF) infusion in patients with GH deficiency.
September 1985, Acta endocrinologica,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Effects of human pancreatic growth hormone-releasing factor-40 on serum growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and somatomedin-C concentrations in normal women throughout the menstrual cycle.
November 1984, The Journal of clinical endocrinology and metabolism,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
The response of normal subjects and patients with idiopathic growth hormone deficiency to continuous infusion of human pancreatic growth hormone releasing factor 1-44.
November 1984, Clinical endocrinology,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency.
December 1986, European journal of pediatrics,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
[Human pancreatic growth hormone-releasing factor].
January 1986, Sheng li ke xue jin zhan [Progress in physiology],
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Circulating somatomedin-C levels and the effect of growth hormone-releasing factor on plasma levels of growth hormone and somatostatin-like immunoreactivity in obese children.
January 1987, European journal of pediatrics,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Growth hormone and somatomedin-C response to synthetic human pancreatic tumor GH-releasing factor in hypopituitary and constitutionally short children.
December 1986, Journal of endocrinological investigation,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Effects of corticotropin releasing factor and growth hormone releasing factor on pituitary hormone secretion in patients with congenital thyrotropin deficiency. Abnormal response of growth hormone to corticotropin releasing factor.
December 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Growth hormone treatment and somatomedin-C levels.
November 1984, The Journal of pediatrics,
J L Borges, and R M Blizzard, and M C Gelato, and R Furlanetto, and A D Rogol, and W S Evans, and M L Vance, and D L Kaiser, and R M MacLeod, and G R Merriam, and D L Loriaux, and J Spiess, and J Rivier, and W Vale, and M O Thorner
Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour.
November 1982, Nature,
Copied contents to your clipboard!